Concordia International Corp. (CXRXF) Analysts See $-0.07 EPS

July 14, 2018 - By Robert Shackelford

Analysts expect Concordia International Corp. (OTCMKTS:CXRXF) to report $-0.07 EPS on August, 10.They anticipate $0.26 EPS change or 136.84 % from last quarter’s $0.19 EPS. After having $-0.19 EPS previously, Concordia International Corp.’s analysts see -63.16 % EPS growth. The stock increased 4.05% or $0.0078 during the last trading session, reaching $0.2003. About 98,993 shares traded. Concordia International Corp. (OTCMKTS:CXRXF) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $10.68 million. The firm operates through two divisions, Concordia International and Concordia North America. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.